Table 1.
Comparison of demographic, clinical, and pathologic features between PSP-CI and PSP-NC
| Features | Total (N = 121) |
PSP-CI (N = 90) |
PSP-NC (N = 31) |
P value |
|---|---|---|---|---|
| Male, No. (%) | 74 (61%) | 55 (61%) | 19 (61%) | 0.85 |
| Age at onset, years | 66 ± 8 | 66 ± 8 | 66 ± 9 | 0.74 |
| Age at death, years | 74 ± 8 | 74 ± 8 | 74 ± 9 | 0.98 |
| Disease duration, years | 7 (5, 9) | 7 (5, 9) | 7 (5, 12) | 0.73 |
| Family history of dementia | 28 (23%) | 23 (26%) | 5 (16%) | 0.41 |
| Family history of Parkinsonism | 21 (17%) | 16 (18%) | 6 (19%) | 0.94 |
| Having clinical diagnosis of PSP | 91 (75%) | 70 (78%) | 21 (68%) | 0.38 |
| Pathology | ||||
| Brain weight, grams | 1180 ± 140 | 1160 ± 140 | 1230 ± 150 | 0.02 |
| Braak NFT stage | II (II, III) | II (II, III) | II (II, III) | 0.59 |
| Thal amyloid phase | 0 (0, 3) | 0 (0, 3) | 1 (0, 3) | 0.20 |
| Alzheimer’s disease | 15 (12%) | 9 (10%) | 6 (19%) | 1.00 |
| Argyrophilic grain disease | 31 (26%) | 23 (26%) | 8 (26%) | 1.00 |
| Hippocampal sclerosis | 1 (1%) | 1 (1%) | 0 (0%) | 1.00 |
| Cerebrovascular pathology | 14 (12%) | 10 (11%) | 4 (13%) | 1.00 |
| Lewy-related pathology | 9 (7%) | 8 (9%) | 1 (3%) | 1.00 |
| Total tau burden | 6 (4, 8) | 6 (5, 8) | 6 (4, 8) | <0.001 |
Values are n (%), mean ± SD, and median (25th, 75th %-tile). Abbreviations: NFT, neurofibrillary tangle; PSP-CI, progressive supranuclear palsy with cognitive impairment; PSP-NC, progressive supranuclear palsy without cognitive impairment.